[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Dartmouth-Hitchcock Medical Center\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":629},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,64,0,25,[9,50,75,102,133,152,182,202,226,253,276,299,318,348,371,399,420,440,460,481,502,529,555,575,599],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":34,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100486305","colonoscopy-vs-stool-testing-for-older-adults-with-colon-polyps-100486305",false,"NCT05612347","Colonoscopy vs Stool Testing for Older Adults With Colon Polyps","Colonoscopy Versus Stool-based Testing for Older Adults With a History of Colon Polyps","COOP","Inclusion Criteria:\n\n* English or Spanish speaking\n* Personal history of colorectal polyps\n* Most recent colonoscopy with ≤2 non-advanced polyps\n* Currently due or coming due within 12 months for colonoscopy\n* Able to provide written informed consent\n\nExclusion Criteria:\n\n* Personal history of colorectal cancer\n* Personal history of genetic syndrome with high risk for colorectal cancer (e.g. Lynch Syndrome, Familial Adenomatous Polyposis Syndrome (FAP), or Serrated Polyposis Syndrome)\n* Personal history of inflammatory bowel disease (e.g. ulcerative colitis, Crohn's disease)\n* Most recent colonoscopy with advanced polyp(s) or ≥3 non-advanced polyps\n* Patients unlikely to benefit from polyp surveillance (e.g., history of heart disease or coronary artery disease with treatment in the last 6 months, heart failure affecting function, lung disease requiring use of home oxygen, stroke within the last 4 months, dementia affecting activities of daily living (ADL) or instrumental activities of daily living (IADL), severe liver disease requiring the use of certain medications to control fluid, confusion, or bleeding, severe kidney disease requiring dialysis, or a new cancer diagnosis within the last year)\n* Patients unable to provide written informed consent","ALL","65 Years","82 Years",{"count":22,"type":23},8946,"ESTIMATED","INTERVENTIONAL",[26],"NA","This is a multi-site comparative effectiveness randomized controlled trial (RCT) comparing annual fecal immunochemical testing (FIT) and colonoscopy for post-polypectomy surveillance among adults aged 65-82 with a history of colorectal polyps who are due for surveillance colonoscopy.",[29,30,31,32,33],"Colorectal Polyp","Colorectal Neoplasms","Colorectal Adenoma","Colorectal Cancer","Digestive System Disease",[35,36],"Colonoscopy","Fecal immunochemical test (FIT)","RECRUITING","2026-08-11",{"date":40,"type":41},"2026-08-13","ACTUAL",{"date":43,"type":41},"2023-06-14",{"date":45,"type":23},"2035-12-31",{"name":47,"class":48},"Dartmouth-Hitchcock Medical Center","OTHER",24,{"id":51,"slug":52,"hasResults":12,"nctId":53,"briefTitle":54,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":56,"sex":18,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":61,"studyType":62,"phases":4,"briefSummary":63,"conditions":64,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":4},"100650384","dna-methylation-in-pmr-100650384","NCT07748195","DNA Methylation in PMR","Inclusion Criteria:\n\nAnyone ≥50-89 years old Taking ≥10mg of prednisone or prednisone equivalent at time of enrollment with a stable disease normal ESR and CRP (inflammation markers) which would indicate presence of inflammation or not\n\n* CRP: \\\u003C1.0 mg\u002FdL (some labs report in mg\u002FL → normal is usually \\\u003C3 mg\u002FL)\n* ESR:\n* Men ≥50 years: 0-20 mm\u002Fhr\n* Women ≥50 years: 0-30 mm\u002Fhr Have a PMR diagnosis Able to provide written consent\n\nExclusion Criteria:\n\n* History of concomitant Giant cell arteritis (GCA) any other rheumatological disorders like lupus, arthritis (psoriatic, osteo), scleroderma, sjogrens Active malignancy- presence of tumor by imaging or labs Infection- infection can cause increased levels of innate immune cells making it difficult to differentiate between disease and infection recent surgery- within the past 6 months",true,"50 Years","89 Years",{"count":60,"type":23},50,"4 Weeks","OBSERVATIONAL","Polymyalgia Rheumatica (PMR) is treated with corticosteroids; however, long-term treatment is not feasible due to side effects. Withdrawal of corticosteroids causes a subset of patients to relapse, and there is no current way to understand what underlies this. Our research team has preliminary data from a small clinical study that indicates that different immune effector dynamics during the tapering of steroids correlate with relapse. This was achieved using the DNA methylation-specific immune cell profiling methods that Dr. Christensen has pioneered. What is proposed is a larger prospective study of 50 PMR patients to validate differences in CD4 and CD8 memory cells as a predictor of relapse. Finally, we also focus on the Glucocorticoid Methylation Index (GCMI), which is a collection of 28 CpG islands that are methylated in response to corticosteroids. This will allow our team to determine the predictive power of the GCMI for PMR.",[65],"Polymyalgia Rheumatica (PMR)","NOT_YET_RECRUITING","2026-08-10",{"date":69,"type":41},"2026-08-12",{"date":71,"type":23},"2026-07-20",{"date":73,"type":23},"2027-04-01",{"name":47,"class":48},{"id":76,"slug":77,"hasResults":12,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":12,"sex":18,"minAge":82,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":24,"phases":85,"briefSummary":86,"conditions":87,"keywords":90,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":101},"100606361","remote-evaluation-and-alerting-for-collaborative-health-reach-in-depression-100606361","NCT07174557","Remote Evaluation and Alerting for Collaborative Health (REACH) in Depression","Beyond the Clinic: Enhancing Depression Surveillance With a Digital Biomarker","Inclusion Criteria:\n\n* Adult patients (18 years or older)\n* Treated for depression within Dartmouth Health collaborative care model (CoCM) sites who are discharged from CoCM without depression (PHQ-9 \\\u003C 10)\n* Have access to and ability to use a smartphone (Android version ≥ 6 or iOS version ≥ 11).\n\nExclusion Criteria:\n\n* Identified as high risk due to active suicidality, psychosis, or bipolar disorder - Discharged from CoCM with ongoing depressive symptoms (PhQ-9 \\> 10","18 Years",{"count":84,"type":23},320,[26],"Researchers hope to see if the data smartphones collect continuously can be used to predict if patient's depression symptoms will return. They will do this by collecting data from patient's smartphones and comparing it to their depression symptoms. If this method is successful, researchers could develop a smartphone application to help healthcare providers better monitor patient's depression and intervene earlier if symptoms return.",[88,89],"Depression","Major Depressive Disorder",[88,91,92,93],"Smartphone monitoring","Risk detection","Collaborative care","2026-08-09",{"date":38,"type":41},{"date":97,"type":41},"2026-05-20",{"date":99,"type":23},"2028-06-30",{"name":47,"class":48},2,{"id":103,"slug":104,"hasResults":12,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":4,"eligibilityCriteria":108,"healthyVolunteers":12,"sex":18,"minAge":82,"maxAge":4,"enrollmentInfo":109,"targetDuration":4,"studyType":24,"phases":111,"briefSummary":113,"conditions":114,"keywords":116,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":132},"100596270","phase-2-24bro681--alternating-gnp-and-mfolfirinox-for-br-pdac-100596270","NCT07043270","24BRO681 : Alternating Gnp and mFOLFIRINOX for BR-PDAC","24BRO681 : Neoadjuvant Therapy With Alternating Gemcitabine Plus Nab-Paclitaxel and mFOLFIRINOX for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Diagnosis of BR-PDAC. The resectability should be officially determined with surgical oncologists at the Dartmouth Cancer Center (DCC) GI multidisciplinary Tumor Board based on NCCN Guidelines Version 2.2024 Pancreatic Adenocarcinoma.\n* Patients must be able and willing to provide informed consent.\n* Contrast-enhanced CT scan of the chest, abdomen, and pelvis performed within 45 days before registration.\n* ECOG Performance Status: 0-1.\n* Females of childbearing potential must have a negative pregnancy test done ≤ 14 days prior to study enrollment, and must agree to use a highly effective method of contraception throughout the course of protocol therapy.\n\nExclusion Criteria:\n\n* Any prior receipt of chemotherapy or radiation therapy for PDAC.\n* Known DPYD poor metabolizer genotype.\n* Known BRCA1\u002F2 or PALB2 mutations. If they are found to have BRCA1\u002F2 or PALB2 mutation after inclusion to the trial, the participant will be taken off of protocol therapy (since platinum-containing therapy is preferred for these patients).\n* Any confirmed second malignancy that is likely to require systemic therapy during the study period, in the opinion of the enrolling investigator.\n* Any of the following baseline laboratory abnormalities:\n\n  * Absolute neutrophil count (ANC) \\\u003C 2,500\u002Fmm3\n  * Platelet count \\\u003C 100,000\u002Fmm3\n  * Hemoglobin \\\u003C 7 g\u002FdL\n  * Creatinine \\> 1.5 x upper limit of normal (ULN)\n  * Total bilirubin \\> 1.5 x ULN\n  * AST\u002FALT \\> 5 x ULN\n* Any peripheral sensory neuropathy that meaningfully impairs performance of instrumental activities of daily living, as evaluated by the enrolling investigator.\n* Patients who are unable to provide informed consent.\n* Patients who are pregnant or breastfeeding.\n* Patients who are incarcerated.",{"count":110,"type":23},35,[112],"PHASE2","The purpose of this research is to study the effects and safety of alternating neoadjuvant chemotherapy on borderline resectable pancreatic cancer.",[115],"Pancreas Adenocarcinoma",[117,118,119,120,121,122,123],"mFOLFIRINOX","Gemcitabine","Nab-Paclitaxel","Neoadjuvant alternating chemotherapy","Resectable Pancreatic cancer","BR-PDAC","Pancreatic Cancer","2026-08-04",{"date":126,"type":41},"2026-08-06",{"date":128,"type":41},"2025-09-29",{"date":130,"type":23},"2029-07-01",{"name":47,"class":48},1,{"id":134,"slug":135,"hasResults":12,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":4,"eligibilityCriteria":139,"healthyVolunteers":12,"sex":18,"minAge":140,"maxAge":4,"enrollmentInfo":141,"targetDuration":4,"studyType":24,"phases":142,"briefSummary":143,"conditions":144,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":146,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":132},"100558203","d20054litt-for-spine-tumors-100558203","NCT06548061","D20054;LITT for Spine Tumors","Single Center Observational Study Using Spinal Laser Interstitial Thermal Therapy (sLITT) in the Treatment of Spine Metastases and Tumors","Inclusion Criteria:\n\n1. Histology confirmed spinal tumor involving the T2-T12 spine segments.\n2. Indication for spine stereotactic radiosurgery or palliative intervention.\n3. Normal neurologic exam at the time of presentation (Frankel grade E).\n\nExclusion Criteria:\n\n1. Contraindication to MRI\n2. ANY neurologic deficit\n3. Tumor spanning more than 3 consecutive vertebral segments\n4. Contraindication to general anesthesia\n5. Pregnancy","19 Years",{"count":7,"type":23},[26],"The objective of this clinical study is to evaluate the efficacy and safety of spinal laser interstitial therapy in the treatment of metastatic spinal tumors. The investigators hypothesize that rates of local tumor control are comparable between conventional open surgical techniques and spinal laser interstitial therapy.",[145],"Spinal Metastases",{"date":126,"type":41},{"date":148,"type":23},"2028-01-01",{"date":150,"type":23},"2031-06-30",{"name":47,"class":48},{"id":153,"slug":154,"hasResults":12,"nctId":155,"briefTitle":156,"officialTitle":157,"acronym":4,"eligibilityCriteria":158,"healthyVolunteers":12,"sex":18,"minAge":159,"maxAge":160,"enrollmentInfo":161,"targetDuration":4,"studyType":24,"phases":163,"briefSummary":164,"conditions":165,"keywords":168,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":175,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":181},"100617965","plan-and-protect-safety-planning-for-teens-in-rural-emergency-departments-100617965","NCT07325474","Plan and Protect: Safety Planning for Teens in Rural Emergency Departments","Development & Implementation of Culturally Sensitive Safety Planning to Reduce Suicide Risk in Adolescents Seeking Care in Rural Emergency Departments","Inclusion criteria for children:\n\n* 12-17 years of age (and their parent\u002Fcaregiver(s))\n* Ability to speak and complete surveys in English\n* History of emergency department visit for suicidality, self-harm or mental health crisis\n* Medically stable\n\nExclusion criteria for children:\n\n* Cognitive or developmental delays that preclude program participation based on clinical team assessment\n* Diagnosis of psychosis\n* Primary diagnosis of an eating disorder\n* Parent\u002Fguardian not able to provide consent in English\n* Clinical team concern for patient or staff safety based upon active behavioral concerns\n* Parent\u002Fguardian not available to provide consent (e.g youth is in child protective custody\u002Fward of the state)\n\nInclusion criteria for parents\u002Fcaregivers:\n\n* Parent or caregiver of an eligible child\n* 18 years old or older\n* Ability to speak and complete surveys in English\n\nExclusion criteria for parents\u002Fcaregivers:\n\n-Inability to understand key aspects of the study","12 Years","17 Years",{"count":162,"type":23},550,[26],"The goal of this observational study is to determine whether implementing a culturally sensitive, tablet-based safety planning program called Plan \\& Protect (P\\&P) within rural emergency departments can improve home safety and reduce suicide risk in adolescents presenting with suicidality.\n\nThe main questions it aims to answer are:\n\n* Will implementing P\\&P increase caregiver-reported home safety (reduce access to firearms and unsafe medication storage) for adolescents 12-17 years old presenting to rural EDs with suicidal ideation, self-harm, or mental health crisis?\n* Will implementing P\\&P decrease adolescent-reported perceived suicide risk and related outcomes (e.g., suicide events, and attendance at follow-up mental healthcare)?\n\nResearchers will compare outcomes for adolescents and caregivers receiving P\\&P (implemented as the new standard of care at sites during the intervention periods) to those receiving usual care (prior to P\\&P implementation at those hospitals) to see if P\\&P increases home safety and decreases suicide risk and related healthcare utilization.\n\nParticipants will, if clinically appropriate:\n\n* Complete the tablet-based P\\&P modules during their ED visit\n* Complete self-report measures at baseline, \\~30 days, and \\~3 months post-discharge\n* A subset will also participate in semi-structured interviews",[166,167],"Suicide Ideation","Suicide Attempt",[169,170,171,172,173],"Suicide","Safety Planning","Adolescent","Mental Health Services","Emergency Services","2026-08-02",{"date":124,"type":41},{"date":177,"type":23},"2026-08-01",{"date":179,"type":23},"2029-04-30",{"name":47,"class":48},4,{"id":183,"slug":184,"hasResults":12,"nctId":185,"briefTitle":186,"officialTitle":186,"acronym":4,"eligibilityCriteria":187,"healthyVolunteers":12,"sex":18,"minAge":82,"maxAge":4,"enrollmentInfo":188,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":190,"conditions":191,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":201,"locationsCount":132},"100575840","advancing-antimicrobial-photodynamic-therapy-to-prevent-infection-in-osseointegrated-prosthesis-patients-100575840","NCT06777511","Advancing Antimicrobial Photodynamic Therapy to Prevent Infection in Osseointegrated Prosthesis Patients","Inclusion Criteria:\n\n* All patients with osseointegrated prostheses 18 years of age or older\n\nExclusion Criteria:\n\n* Ongoing infection\n* Pregnant\n* Anticipated issues with compliance or follow-up",{"count":189,"type":23},10,"This will be a prospective observational trial enrolling 20 patients with osseointegrated prostheses. Participants will be recruited from the orthopaedic outpatient clinic at Walter Reed National Military Medical Center in Bethesda, MD.\n\nAll eligible consenting patients will undergo daily stoma management per standard of care.\n\nPatients will integrate antimicrobial photodynamic therapy into their stoma management program. The first treatment will take place in the orthopaedic clinic. All others will take place at home. Topical 5-ALA will be applied to the metal at the penetration site. After 2 hours, the light delivery device will be utilized and light will be administered for 15 minutes.\n\nData collection: After obtaining informed consent, study personnel will record injury-specific variables, surgery-specific variables, other variables related to their hospital course, demographic variables as well as comorbidities on the study case report forms (CRFs). They will obtain this information directly from the participant, from the participant's medical record, and the participant's treating orthopaedic surgeon or other health care providers. Baseline data collection points include participant characteristics and amputation details such as age, sex, comorbidities, highest education level achieved, social support, initial reason for amputation, type of amputation and all surgical dates. Study participants will be followed at 1 and 2 weeks after initiation of PDT treatment. To ensure research participant safety, serious adverse events (SAEs) will be documented and promptly submitted to the local IRB as per the required reporting processes.\n\nFollow-up: Study participants will be followed at 1 week and 2 weeks.",[192,193],"Amputation","Osseointegration","2026-07-28",{"date":196,"type":41},"2026-07-29",{"date":198,"type":23},"2026-10",{"date":200,"type":23},"2028-10",{"name":47,"class":48},{"id":203,"slug":204,"hasResults":12,"nctId":205,"briefTitle":206,"officialTitle":206,"acronym":207,"eligibilityCriteria":208,"healthyVolunteers":12,"sex":18,"minAge":209,"maxAge":4,"enrollmentInfo":210,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":212,"conditions":213,"keywords":215,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":219,"startDateStruct":221,"completionDateStruct":223,"leadSponsor":225,"locationsCount":132},"100397704","restoration-of-thumb-strength-and-function-in-basal-joint-arthritis-a-comparative-effectiveness-trial-restart-100397704","NCT04458584","Restoration of Thumb Strength and Function in Basal Joint Arthritis: A Comparative Effectiveness Trial (RESTART)","RESTART","Inclusion Criteria:\n\n* Males and females 21 years of age or older;\n* Undergoing elective non-prosthetic, primary basal joint arthroplasty;\n* Patient has necessary mental capacity to participate and comply with study protocol;\n* Patient is willing and able to give informed consent; and\n* Patient is willing to participate under the care of their chosen surgeon.\n\nExclusion Criteria:\n\n* Patients with a diagnosis of rheumatoid arthritis, systemic lupus erythematosis, psoriatic arthritis, or other related inflammatory arthritis;\n* Patients undergoing simultaneous bilateral hand procedures of any nature;\n* Women who are pregnant or breastfeeding;\n* Women of reproductive potential unless there is a negative urine pregnancy test on the day of surgery. Women of child bearing potential include those who are premenopausal who have not had a bilateral oophorectomy, hysterectomy or tubal ligation. Post-menopausal is defined as not having had a menstrual period for at least one calendar year.\n* Vulnerable patient populations including prisoners and institutionalized individuals.","21 Years",{"count":211,"type":23},165,"The purpose of this study is to evaluate the basis for three widely held fundamental tenets about surgical intervention for thumb basal joint arthritis;\n\n1. Trapeziectomy with ligament reconstruction and metacarpal stabilization is associated with superior functional outcomes and strength,\n2. Preservation of the arthroplasty space correlates with functional outcomes, pain relief, and restoration of strength after basal joint arthroplasty, and\n3. Mitigation of metacarpophalangeal joint (MCPJ) hyperextension optimizes postoperative strength after basal joint arthroplasty, regardless of surgical technique.\n\nIt is hypothesized that thumb basal joint arthroplasty with metacarpal stabilization, by either ligament reconstruction (I) or suture suspension (II), provides greater improvement in grip and pinch strength, and better hand function, than might be achieved following provision of pain relief alone by simple trapeziectomy (III). Preservation of the arthroplasty space will correlate positively, and MCPJ hyperextension will correlate negatively, with improved thumb function and lateral pinch strength.\n\nPrimary Aims (within 3 procedure cohorts):\n\n1. Compare pre-operative pinch and grip strength as well as patient-reported outcomes (PROs) for pain in patients before and after lidocaine injection of the trapeziometacarpal joint, prior to thumb basal joint arthroplasty;\n2. Compare post-operative pinch and grip strength and PROs for pain and function at 3 and 6 months after thumb basal joint arthroplasty with pre-operative values before and after lidocaine injection;\n3. Correlate preservation of dynamic arthroplasty space as measured on a stress radiograph with postoperative improvement in pinch and grip strength, and PROs for pain and function;\n4. Correlate dynamic MCP joint position and laxity with change in strength and patient-reported pain and function to define optimal MCPJ position.\n\nSecondary Aims (between 3 procedure cohorts):\n\n1. Compare change in pre- and post-operative pinch and grip strength and PROs for pain and function between patients having basal joint arthroplasty with and without specific metacarpal stabilization;\n2. Compare preservation of the dynamic arthroplasty space and improvement in strength and patient-reported pain and function between arthroplasty groups; and\n3. Compare changes in pinch and grip strength and PROs for pain and function with dynamic MCPJ position between arthroplasty groups.\n4. Compare postoperative neuritis and complications between surgical groups.",[214],"Osteoarthritis Thumb",[216,217,218],"Ligament reconstruction","Suspensionplasty","Arthroscopic Trapeziectomy",{"date":220,"type":41},"2026-07-30",{"date":222,"type":41},"2020-06-29",{"date":224,"type":23},"2027-03-31",{"name":47,"class":48},{"id":227,"slug":228,"hasResults":12,"nctId":229,"briefTitle":230,"officialTitle":230,"acronym":4,"eligibilityCriteria":231,"healthyVolunteers":12,"sex":18,"minAge":232,"maxAge":233,"enrollmentInfo":234,"targetDuration":4,"studyType":24,"phases":236,"briefSummary":237,"conditions":238,"keywords":242,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":246,"lastUpdatePostDateStruct":247,"startDateStruct":248,"completionDateStruct":250,"leadSponsor":252,"locationsCount":132},"100649560","hobscotch-youth-and-young-adults-100649560","NCT07735715","HOBSCOTCH-YOUTH and Young Adults","Inclusion Criteria:\n\n* Inclusion Criteria for Young Adults with Epilepsy (YAWE) and Youth with Epilepsy (YWE):\n\n  * Age 18 - 29 years for YAWE\n  * Age 13 - 17 years for YWE\n  * For YWE at least one parent or legal guardian provides consent and agrees to participate\n  * Diagnosis of epilepsy (controlled or uncontrolled seizures)\n  * Subjective cognitive complaints (memory, attention, learning, problem solving, executive function, planning)\n  * Literate and proficient in English\n  * Telephone access\n  * Internet Access.\n\nInclusion Criteria for Parent of Youth with Epilepsy (YWE):\n\n* Parent or legal guardian of a youth with epilepsy (age 13 - 17 years)\n* Literate and proficient in English\n* Telephone access\n* Internet Access\n\nExclusion Criteria:\n\n* Active psychosis (any participant)\n* Illicit substance abuse (any participant)\n* Severe cognitive\u002Fintellectual disability (any participant)\n* YWE cannot participate without a parent and parent's consent (or legal guardian)\n* YWE cannot participate without assent even if a parent or legal guardian gives consent","13 Years","29 Years",{"count":235,"type":23},300,[26],"The goal of this clinical trial is to learn more about the home-based epilepsy self-management program, HOBSCOTCH, for improving cognitive function (thinking and memory) and quality of life specifically in young adults, ages 18 - 29 years, who have epilepsy. It will also learn if a modification of the program for youth with epilepsy, ages 13 - 17, improves thinking and memory and quality of life and reduces stress for their parents.\n\nResearchers will enroll 260 young adults with epilepsy and 40 youth with epilepsy and their parent or guardian. Researchers will compare responses to questionnaires and surveys before and after participation in the HOBSCOTCH program to see if thinking, memory and quality of life have improved for young adults and youth with epilepsy and to see if parents have improved quality of life as well.\n\nParticipants will:\n\n* Attend 9 weekly one-hour sessions of the HOBSCOTH program in their homes with a one-on-one coach using their computer or their phone; youth with epilepsy (ages 13 - 17) will attend alongside a parent or legal guardian.\n* Keep a short daily diary about their seizures and activity in the program using a smart phone app(lication)\n* Complete surveys and questionnaires before HOBSCOTCH and 3 months and 6 months later.\n\nThere are no study visits to a medical center. HOBSCOTCH is a virtual or telehealth intervention.",[239,240,241],"Epilepsy","Cognitive Dysfunction, Cognitive Disorder","Memory and Thinking Problems",[239,243,240,244,245],"Seizures","Memory and thinking problems","Epilepsy Self-Management","2026-07-24",{"date":220,"type":41},{"date":249,"type":23},"2026-09-01",{"date":251,"type":23},"2029-03-01",{"name":47,"class":48},{"id":254,"slug":255,"hasResults":12,"nctId":256,"briefTitle":257,"officialTitle":258,"acronym":4,"eligibilityCriteria":259,"healthyVolunteers":56,"sex":18,"minAge":260,"maxAge":4,"enrollmentInfo":261,"targetDuration":4,"studyType":24,"phases":263,"briefSummary":264,"conditions":265,"keywords":267,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":246,"lastUpdatePostDateStruct":270,"startDateStruct":271,"completionDateStruct":273,"leadSponsor":275,"locationsCount":132},"100541490","radiation-therapy-for-dupuytrens-contracture-following-non-surgical-release-100541490","NCT06330545","Radiation Therapy for Dupuytren's Contracture Following Non-Surgical Release","A Prospective Clinical Trial of Radiation Therapy for Dupuytren's Contracture Following Surgical and Non-Surgical Release","Inclusion Criteria:\n\n* Age 45 or greater with DC\n* Extension deficit \\>10 degrees\n* Unable to simultaneously place the affected finger and palm flat on a table.\n* Women included in the study will be post-menopausal or using contraception, and a pregnancy test will be performed as standard of care.\n* For patients who are having multiple CCH injections, only the first 2 joints on given hand will be included\n\nExclusion Criteria:\n\n* Unsuccessful non-surgical release (\\> N\u002F1 disease)\n* They develop an open wound during CCH\n* Breast feeding or pregnancy\n* A chronic muscular, neurologic, or neuromuscular disorder affecting the hands.\n* Less than the age of 45\n* They have previously undergone radiation on the hand in which they plan to get CCH injections\n* They are pregnant women, impaired adults or prisoners","45 Years",{"count":262,"type":23},95,[26],"The goal of this study is to learn about preventing recurrence of Dupuytren's Contracture. The main question it aims to answer are:\n\n• Does targeted radiation therapy decrease recurrence of Dupuytren's contracture after treatment with Collagenase Clostridium Histolyticum?\n\nParticipants will undergo:\n\n* Release of Dupuytren's Contracture after Collagenase Clostridium Histolyticum injection\n* Daily radiation therapy treatment for 5 days followed by 6-8 week rest period and then another course of 5 days of radiation therapy",[266],"Dupuytren Contracture",[268,269],"Dupuytren's contracture","radiation therapy",{"date":194,"type":41},{"date":272,"type":41},"2024-09-16",{"date":274,"type":23},"2032-04",{"name":47,"class":48},{"id":277,"slug":278,"hasResults":12,"nctId":279,"briefTitle":280,"officialTitle":281,"acronym":4,"eligibilityCriteria":282,"healthyVolunteers":56,"sex":18,"minAge":260,"maxAge":283,"enrollmentInfo":284,"targetDuration":4,"studyType":24,"phases":286,"briefSummary":287,"conditions":288,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":291,"lastUpdatePostDateStruct":292,"startDateStruct":294,"completionDateStruct":296,"leadSponsor":297,"locationsCount":298},"100607014","implementation-intention-planning-guide-for-fit-colon-cancer-screening-100607014","NCT07183046","Implementation Intention Planning Guide for FIT Colon Cancer Screening","Impact of an Implementation Intention Planning Guide on Fecal Immunochemical Tests (FIT) Completion Rates","Inclusion Criteria:\n\n* Age 45-75\n* Cared for by primary care at General Internal Medicine Clinic, Dartmouth-Hitchcock Medical Center (Lebanon, NH), Dartmouth Hitchcock Clinics Heater Road Primary Care (Lebanon, NH), Dartmouth Hitchcock Clinics Lyme Primary Care (Lyme, NH), or White River Junction Veterans Affairs Medical Center (White River Junction, VT) OR eligible for FIT through VA Mailed FIT Program\n\nExclusion Criteria:\n\n* none","75 Years",{"count":285,"type":23},1600,[26],"Fecal immunochemical tests (FIT) are a primary method of screening for colorectal cancer (CRC). Implementation intention planning involves encouraging completion or eliminating barriers for the participant to make a plan to complete a behavior or activity. This randomized control study seeks to answer whether the addition of an implementation intention guide impacts behaviors when completing FIT screening. The primary objective includes determining if the implementation intention guide increases completion rate of screening FIT. The secondary objectives is whether this intervention decreases the lab sample rejection rate and reduces the duration between sample collection and laboratory receipt\u002Fevaluation of screening FIT.",[289,290],"Fecal Immunochemical Test","Colorectal Cancer Screening","2026-07-22",{"date":293,"type":41},"2026-07-23",{"date":295,"type":23},"2026-10-01",{"date":99,"type":23},{"name":47,"class":48},5,{"id":300,"slug":301,"hasResults":12,"nctId":302,"briefTitle":303,"officialTitle":303,"acronym":4,"eligibilityCriteria":304,"healthyVolunteers":56,"sex":18,"minAge":82,"maxAge":4,"enrollmentInfo":305,"targetDuration":4,"studyType":24,"phases":307,"briefSummary":308,"conditions":309,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":291,"lastUpdatePostDateStruct":312,"startDateStruct":313,"completionDateStruct":315,"leadSponsor":317,"locationsCount":132},"100264771","internet-based-psychological-support-100264771","NCT02726061","Internet Based Psychological Support","Inclusion Criteria:\n\n* Adult employees (age 18 and older) and faculty attending the EAP programs of DHMC and Dartmouth College complaining of depression.\n* Any Adult (age 18 or older)\n\nExclusion Criteria:\n\n* None",{"count":306,"type":23},500,[26],"The investigators have developed interactive, multimedia-intensive, computer-based treatment programs that include depression (Problem-Solving Therapy), stress management, and conflict management. Together the three modules are called PATH.\n\nThe problem-solving module is based on an evidence-based psychotherapy called Problem-Solving Therapy in which depressed patients identify problems in their lives and work through a structured format for solving these problems. We have subjected the problem-solving module to Phase 1-3 feasibility, acceptability and efficacy trials which have been positive and without adverse events.\n\nThe conflict program uses a cognitive-behavioral-therapy-based approach. The program includes a conflict briefing, an interactive conflict simulation, a conflict assessment tool, an interactive training exercise in interest-based negotiation, and a cognitive restructuring exercise.\n\nThe stress program also uses a cognitive behavioral therapy (CBT) approach. In the program, the mentor introduces the \"stress pyramid\", which demonstrates how stress triggers can lead to different feelings, actions and thoughts, which are analogs to the CBT realms of dysfunctional emotions, maladaptive behaviors, and faulty cognitive processes. The stress management content is delivered over 6 sessions, with each session including exercises in the 3 domains of thoughts, feelings, and actions. The program includes briefings, cognitive restructuring exercises, interactive scenarios, and self-assessments. This program has been evaluated with law and business students and was shown effective in reducing stress levels.\n\nThe purpose of the current study is to make the problem-solving, stress, and the conflict modules available through the internet for any adult 18 or older in order to assess their feasibility, acceptability and effectiveness under naturalistic conditions.",[88,310,311],"Stress","Conflict Resolution",{"date":293,"type":41},{"date":314,"type":41},"2016-02",{"date":316,"type":23},"2031-02",{"name":47,"class":48},{"id":319,"slug":320,"hasResults":12,"nctId":321,"briefTitle":322,"officialTitle":323,"acronym":324,"eligibilityCriteria":325,"healthyVolunteers":12,"sex":18,"minAge":82,"maxAge":4,"enrollmentInfo":326,"targetDuration":4,"studyType":24,"phases":328,"briefSummary":329,"conditions":330,"keywords":332,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":341,"lastUpdatePostDateStruct":342,"startDateStruct":343,"completionDateStruct":345,"leadSponsor":347,"locationsCount":101},"100609978","the-agenda-setting-for-kidney-disease-open-pilot-trial-100609978","NCT07221604","The Agenda-Setting for Kidney Disease Open Pilot Trial","Setting the Agenda: An Open Pilot of a Structured Clinical Visit Agenda-Setting Intervention for Rural-Residing People With Advanced Chronic Kidney Disease","ASK","Inclusion Criteria:\n\n* Adults \\>18 years old who have been diagnosed with advanced CKD (stages 4-5).\n* Care partners, clinicians and staff supporting these CKD patients who are willing and able to provide informed consent\n* English-speaking\n* Able to provide informed consent\n* Patient must be attending outpatient visits \\*(in-person and\u002For telehealth allowable).\n\nExclusion Criteria:\n\n* Children under 18 years old will not be included\n* Non-English-speaking patients and\u002For care partners\n* Patients on dialysis\n* Individuals unable or unwilling to provide informed consent",{"count":327,"type":23},30,[26],"The goal of this open pilot is to practice using an intervention and surveys before a larger pilot stepped wedge clinical trial. The intervention the researchers plan to use is Chronic Kidney Disease (CKD) Topics, and it is a structured clinical agenda-setting intervention (SAS), or a customized list of discussion topics. The people the researchers are practicing using the SAS with have advanced CKD (stages 4-5), and many of them live in rural areas. The researchers will practice administering CKD Topics, along with survey questions. By doing the open pilot, the researchers will learn if they need to modify the steps they plan to take in the larger trial.\n\nThe main questions the researchers aim to answer are:\n\n* Do the steps for identifying eligible participants work?\n* Do the steps for administering CKD Topics work?\n* Do the steps to administer survey questions work?",[331],"Chronic Kidney Disease Stage 4",[333,334,335,336,337,338,339,340],"Chronic kidney disease","Chronic kidney disease stage 4","Chronic kidney disease stage 5","Agenda-setting","Patient engagement","Rural","Participatory research","Open pilot","2026-07-21",{"date":293,"type":41},{"date":344,"type":41},"2026-05-19",{"date":346,"type":23},"2026-09",{"name":47,"class":48},{"id":349,"slug":350,"hasResults":12,"nctId":351,"briefTitle":352,"officialTitle":353,"acronym":354,"eligibilityCriteria":355,"healthyVolunteers":12,"sex":18,"minAge":356,"maxAge":4,"enrollmentInfo":357,"targetDuration":4,"studyType":24,"phases":359,"briefSummary":360,"conditions":361,"keywords":363,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":341,"lastUpdatePostDateStruct":366,"startDateStruct":367,"completionDateStruct":368,"leadSponsor":370,"locationsCount":132},"100602757","askids-inpatient-agenda-setting-study-for-hospitalized-children-with-medical-complexity-100602757","NCT07127666","ASKids! Inpatient Agenda-Setting Study for Hospitalized Children With Medical Complexity","Centering Children and Care Partners in Complex Pediatric Hospital Stays: Evaluation of a Structured Inpatient Agenda-setting Intervention for Multidisciplinary Family Meetings","ASKids","Inclusion Criteria:\n\n* Pediatric Inpatients: Children aged 7-17 years\n* Can communicate in English\n* Able to provide verbal assent, with consent from their care partner\n* Dartmouth Hitchcock Medical Center pediatric patient who currently or has recently (within the last 3 months) been hospitalized with a length of stay of 4≥ days Care Partners: - Adults aged 18≥ years\n* Can communicate in English\n* Able to provide verbal consent\n* Care partners of Dartmouth Hitchcock Medical Center pediatric patients who are currently or have recently (within the last 3 months) been hospitalized with a length of stay of 4≥ days\n\nExclusion Criteria:\n\n* For pediatric inpatients, children \\\u003C aged 7\n* For care partners, children aged \\\u003C18 years\n* Cannot communicate in English\n* For pediatric inpatients, unable to provide verbal assent\n* For care partners, unable to provide consent\n* Prisoners","7 Years",{"count":358,"type":23},20,[26],"The goal of this open pilot is to co-design and test a clinical agenda-setting intervention in the inpatient pediatric environment. We pilot a co-designed structured agenda-setting intervention (SAS) for multi-family meetings about children with medical complexity. Our open pilot will evaluate the feasibility and acceptability of using the SAS during routine multidisciplinary family meetings (MFM) at Dartmouth Hitchcock Medical Center. By doing an open pilot, researchers will learn if the agenda-setting instrument and implementation process are feasible and acceptable to patients, their care partner and their clinicians.",[362],"Medical Complexity",[364,365],"clinical agenda-setting","pediatric inpatient care",{"date":291,"type":41},{"date":177,"type":23},{"date":369,"type":23},"2026-12",{"name":47,"class":48},{"id":372,"slug":373,"hasResults":12,"nctId":374,"briefTitle":375,"officialTitle":375,"acronym":4,"eligibilityCriteria":376,"healthyVolunteers":12,"sex":18,"minAge":82,"maxAge":377,"enrollmentInfo":378,"targetDuration":4,"studyType":24,"phases":380,"briefSummary":381,"conditions":382,"keywords":385,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":341,"lastUpdatePostDateStruct":392,"startDateStruct":393,"completionDateStruct":395,"leadSponsor":397,"locationsCount":398},"100585148","enhancing-engagement-by-integrating-goals-and-concerns-that-matter-to-patients-100585148","NCT06898593","Enhancing Engagement by Integrating Goals and Concerns That Matter to Patients","Inclusion Criteria:\n\n* Patients enrolled in the Collaborative Care Model (CoCM) at Dartmouth Health\n\nExclusion Criteria:\n\n* Patients not enrolled in the Collaborative Care Model (CoCM) at Dartmouth Health","100 Years",{"count":379,"type":23},2448,[26],"The goal of this clinical trial is to learn if adding patients' goals and concerns to measurement-based collaborative care can tailor care and provide a more holistic view of treatment, thereby improving engagement in care among adult patients receiving collaborative care. The main questions it aims to answer are:\n\n* Does using a clinical decision support system (which includes an enhanced pre-visit questionnaire and patient-level dashboard) improve patient engagement in the collaborative care model?\n* Does using a clinical decision support system improve patient and clinician satisfaction with care?\n\nResearchers will compare the enhanced collaborative care with traditional collaborative care.\n\nPatient participants will complete pre-visit questionnaires before their collaborative care appointments. Responses will be viewed by the clinician and\u002For patient in a visual dashboard inside the electronic health record.",[383,384],"Anxiety Disorders","Depression Disorders",[386,387,388,389,88,390,391],"Collaborative Care Model","pre-visit questionnaire","dashboard","clinical decision support system","Anxiety","integrated behavioral health and primary care",{"date":291,"type":41},{"date":394,"type":41},"2025-04-02",{"date":396,"type":23},"2028-07-31",{"name":47,"class":48},6,{"id":400,"slug":401,"hasResults":12,"nctId":402,"briefTitle":403,"officialTitle":404,"acronym":4,"eligibilityCriteria":405,"healthyVolunteers":12,"sex":18,"minAge":82,"maxAge":4,"enrollmentInfo":406,"targetDuration":4,"studyType":24,"phases":407,"briefSummary":408,"conditions":409,"keywords":411,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":341,"lastUpdatePostDateStruct":414,"startDateStruct":415,"completionDateStruct":417,"leadSponsor":419,"locationsCount":132},"100582067","bioimpedance-for-ortho-trauma-100582067","NCT06858488","Bioimpedance for Ortho Trauma","A Pilot Study on the Technical Feasibility of an Electrical Impedance Tomography Device for Soft Tissue Injury Following High Energy Extremity Fractures","Inclusion Criteria:\n\n* Age 18 years or older\n* High energy closed extremity fracture\n* Provision of informed consent\n\nExclusion Criteria:\n\n* Metatarsal fractures\n* Injury to both lower extremities precluding contralateral imaging\n* Presence of an implanted electronic device (e.g. pacemaker, vagal stimulator, deep brain stimulator) or electrodes or electrical wires.\n* Currently pregnant, potentially pregnant, or lactating women",{"count":327,"type":23},[26],"Patients with high-energy extremity trauma will undergo imaging with an EIT device in the Emergency Department, Operating Room, Orthopaedic Clinic, and In-patient hospital rooms. The EIT device is an electrical impedance tomography system.",[410],"Trauma Injury",[412,413],"Orthopedics","Extremity fracture",{"date":291,"type":41},{"date":416,"type":41},"2025-03-20",{"date":418,"type":23},"2028-07",{"name":47,"class":48},{"id":421,"slug":422,"hasResults":12,"nctId":423,"briefTitle":424,"officialTitle":425,"acronym":4,"eligibilityCriteria":426,"healthyVolunteers":56,"sex":18,"minAge":427,"maxAge":428,"enrollmentInfo":429,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":431,"conditions":432,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":341,"lastUpdatePostDateStruct":434,"startDateStruct":435,"completionDateStruct":437,"leadSponsor":439,"locationsCount":132},"100523959","mci-speech-in-noise-100523959","NCT06102486","MCI Speech in Noise","Speech Perception in Noise as an Improved Marker for Neurocognitive Dysfunction","Inclusion Criteria:\n\n* Adults diagnosed with or suspected to have MCI (for MCI group) or are cognitively normal (for Control group)\n* Absence of other risk factors that might affect CAP (Central Auditory Processing) performance (e.g., active ear infections, congenital developmental delay, severe hearing loss)\n* Age 55-80\n* Normal hearing sensitivity (\\\u003C40 dB HL Pure Tone Average (average of 500, 1000, 2000 Hz) thresholds bilaterally\n* Normal middle ear function defined by tympanometry (0.3-2.0 ml)\n* Native English speaker\n\nExclusion Criteria:\n\n* Active ear infections or abnormal middle ear pathology\n* Other health condition prohibiting the completion of the CAP test battery\n* Mild to profound peripheral hearing loss (\\>40 dB (decibel) HL (hearing loss) Pure Tone Average (average of 500, 1000, 2000 Hz) bilaterally\n* Adults unable to consent\n* Individuals who are not yet adults (infants, children, teenagers)\n* Prisoners\n* History of CNS (Central Nervous System) disorder that might severely impact cognitive function (e.g., Alzheimer's disease, Parkinson's disease, multiple sclerosis, neurosyphilis, intracranial tumors, history of significant head trauma with loss of consciousness (≥30 min), and cerebrovascular disease)\n* Severe mental illness (e.g., schizophrenia, bipolar disorder)\n* Current, uncontrolled medical condition that could affect cognition (e.g., hypertension)\n* History of substance use disorder within the (other than nicotine\u002Fcaffeine)\n* Non-correctable severe hearing or vision loss\n* Use of \"Cognition Enhancing Drugs\"\n* Frequent, severe headaches (occasional headaches or migraines are fine)","55 Years","80 Years",{"count":430,"type":23},70,"The purpose of this study is to determine whether people with MCI (Mild Cognitive Impairment) and healthy comparison subjects differ with respect to their ability to hear soft sounds and how their brain understands and processes sound. The investigators are also evaluating, within those with MCI, whether the hearing tests are associated with neurocognitive functioning. The investigators are interested in learning whether changes in cognition in those with MCI can be detected using tests of how the brain processes sound. The investigators hypothesize that participants with MCI will score worse on both hearing tests and neurocognitive tests than participants without MCI. Participants are asked to complete multiple types of hearing tests, take a series of neurocognitive tests, and complete a few questionnaires.",[433],"Mild Cognitive Impairment",{"date":291,"type":41},{"date":436,"type":41},"2024-05-18",{"date":438,"type":23},"2026-09-02",{"name":47,"class":48},{"id":441,"slug":442,"hasResults":12,"nctId":443,"briefTitle":444,"officialTitle":445,"acronym":4,"eligibilityCriteria":446,"healthyVolunteers":12,"sex":18,"minAge":82,"maxAge":4,"enrollmentInfo":447,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":449,"conditions":450,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":341,"lastUpdatePostDateStruct":454,"startDateStruct":455,"completionDateStruct":457,"leadSponsor":459,"locationsCount":132},"100499586","oct-in-open-fracture-and-infected-fracture-100499586","NCT05785182","OCT in Open Fracture and Infected Fracture","Optical Coherence Tomography Imaging to Visualize Bacteria or Biofilm on Hardware, Bone and Soft Tissue in Open Fracture and Infected Fracture","Inclusion Criteria:\n\n* Age 18 years or older\n* Open fracture\n* Fracture Related Infection\n\nExclusion Criteria:\n\n* Metatarsal fractures",{"count":448,"type":23},40,"This is a pilot prospective, observational study of patients with open or infected fracture evaluating the feasibility and acceptability of OCT, a light-based imaging modality that requires no drug or contrast agent.",[410,451,452,453],"Trauma","Open Fracture","Fracture Infection",{"date":291,"type":41},{"date":456,"type":41},"2023-03-27",{"date":458,"type":23},"2027-06",{"name":47,"class":48},{"id":461,"slug":462,"hasResults":12,"nctId":463,"briefTitle":464,"officialTitle":465,"acronym":4,"eligibilityCriteria":466,"healthyVolunteers":12,"sex":18,"minAge":82,"maxAge":4,"enrollmentInfo":467,"targetDuration":4,"studyType":24,"phases":469,"briefSummary":470,"conditions":471,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":473,"lastUpdatePostDateStruct":474,"startDateStruct":476,"completionDateStruct":478,"leadSponsor":480,"locationsCount":132},"100647174","pilot-smart-of-a-remotely-delivered-adaptive-physical-activity-intervention-for-breast-cancer-survivors-100647174","NCT07706556","Pilot SMART of a Remotely Delivered, Adaptive Physical Activity Intervention for Breast Cancer Survivors","A Pilot Sequential, Multiple Assignment, Randomized Trial (SMART) of a Remotely Delivered, Adaptive Physical Activity Intervention for Breast Cancer Survivors","Inclusion Criteria:\n\n-≥18 years old\n\n* Within 5 years of completing primary cancer treatment (surgery, chemotherapy, and radiation) for Stage 0-III breast cancer\n* \\\u003C60 mins\u002Fweek moderate-vigorous physical activity (MVPA) with no major changes for the past 6- months\n* Own an Android or iPhone smartphone (or tablet) and willing to use it to complete app-based surveys during assessment periods\n* Willing to wear the ActiGraph monitor during assessment periods\n* Access to internet to complete REDCap survey assessments\n\nExclusion Criteria:\n\n* Non-English speaking\u002Fnot able to read English\n* Evidence of major contraindications for exercise (informed by the 2020 Physical Activity Readiness-Questionnaire (PAR-Q)+)\n* Currently pregnant\n* History of severe mental illness or currently taking mood stabilizing medications (antipsychotics, anticonvulsants, or lithium)\n* Evidence of moderate-severe depressive symptoms (indicated by a score≥ 10 on the Patient Health Questionnaire-8)\n* Evidence of moderate-severe cognitive impairment (indicated by a score \\\u003C 3 on a 6-item cognitive screener)\n* Evidence of clinically significant substance use as indicated by a score of ≥ 2 on the CAGE- AID screener.",{"count":468,"type":23},55,[26],"The goal of this clinical trial is to evaluate the feasibility of randomizing participants to a \"step-up\" intervention pathway when they perform \\\u003C150 minutes of MVPA at the 6-week data collection burst. Participants who performed \\\u003C150 minutes of MVPA at the 6-week data collection burst will be randomized to either continue with the standard intervention or advance to the step-up intervention. The main questions it aims to answer are:\n\n1. What percentage of participants who are eligible for the intervention phase enroll in the intervention phase?\n2. Will participants assigned to the \"step-up\" intervention pathway demonstrate equal or greater rates of study retention and intervention engagement relative to those assigned to the standard intervention arm?\n3. What percentage of the sample is performing \\>150 minutes accelerometer measured MVPA\u002Fweek at the intervention mid-point (week 6-data collection burst) and end-of-study (week 12-data collection burst)?\n4. Do at least 50% of participants assigned to the \"step-up\" intervention pathway achieve a clinically meaningful volume of weekly MVPA by 12-weeks follow-up?\n\nAll participants will:\n\n* Be assigned to either the Affect-based exercise prescription or the Effort-based exercise prescription.\n* Participate in three meetings with the interventionist (an exercise specialist) meant to help them get started increasing weekly exercise. These meetings are the same for all participants.\n* Be asked to wear an activity monitor and respond to brief surveys for 10 consecutive days at 4 points in time: Baseline, 2weeks, 6weeks, and 12weeks.\n\nSome participants (those performing \\\u003C150 minutes of MVPA at the 6-week data collection burst) will be assigned to the step-up intervention pathway. Participants assigned to the step-up intervention pathway will complete 3 additional follow-up meetings with the interventionist. During these meetings, the interventionist will help participants identify opportunities to be more active, set goals, and problem solve barriers to action.",[472],"Breast Cancer","2026-07-10",{"date":475,"type":41},"2026-07-15",{"date":477,"type":41},"2026-06-30",{"date":479,"type":23},"2027-06-03",{"name":47,"class":48},{"id":482,"slug":483,"hasResults":12,"nctId":484,"briefTitle":485,"officialTitle":486,"acronym":4,"eligibilityCriteria":487,"healthyVolunteers":12,"sex":18,"minAge":82,"maxAge":4,"enrollmentInfo":488,"targetDuration":4,"studyType":24,"phases":489,"briefSummary":490,"conditions":491,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":494,"lastUpdatePostDateStruct":495,"startDateStruct":497,"completionDateStruct":499,"leadSponsor":501,"locationsCount":132},"100525322","pulse-width-modulation-100525322","NCT06120231","Pulse-Width Modulation","Pulse-width Modulation During Pedicle Screw Stimulation","Inclusion Criteria:\n\n* A patient will be eligible for study participation once they have been booked for a surgery involving pedicle screw placement and intraoperative neuromonitoring.\n\nExclusion Criteria:\n\n* The study excludes neonates, minors, pregnant women, prisoners and cognitively impaired patients.",{"count":60,"type":23},[26],"The overarching aim of this project is to modulate the pulse-width during stimulation of pedicle screws and record the response thresholds associated with each PWM setting. During this initial phase of the investigation, no further data will be collected.",[492,493],"Spinal Fusion","Spinal Stenosis","2026-07-07",{"date":496,"type":41},"2026-07-09",{"date":498,"type":41},"2023-12-01",{"date":500,"type":23},"2027-10-01",{"name":47,"class":48},{"id":503,"slug":504,"hasResults":12,"nctId":505,"briefTitle":506,"officialTitle":506,"acronym":507,"eligibilityCriteria":508,"healthyVolunteers":12,"sex":18,"minAge":509,"maxAge":82,"enrollmentInfo":510,"targetDuration":4,"studyType":24,"phases":511,"briefSummary":512,"conditions":513,"keywords":516,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":523,"lastUpdatePostDateStruct":524,"startDateStruct":526,"completionDateStruct":527,"leadSponsor":528,"locationsCount":101},"100610105","gastrointestinal-response-of-pediatric-cystic-fibrosis-patients-on-mediterranean-diet-100610105","NCT07223255","Gastrointestinal Response of Pediatric Cystic Fibrosis Patients on Mediterranean Diet","MedDietCF","Inclusion Criteria:\n\n* Male and female pediatric patient with cystic fibrosis age 3 and older\n* Nutritional status defined as a BMI Z-score of at least -1 or above\n* Confirm diagnosis of CF defined by 2 CF causing mutations on genetic testing or sweat chloride greater than 60 mEq\u002FL\n* Children with pancreatic insufficient CF and on PERT\n* Children with pancreatic sufficient CF not on PERT\n* Child must be on a full, solids based diet\n* Family willing to child adhere to an exclusive Mediterranean style diet for a period of 6 months\n* Child must be able to follow-up at regular CF clinic visits and attend any additional study visits if necessary\n\nExclusion Criteria:\n\n* Children with malnutrition\n* Children who require nutritional supplementation via any type of feeding tube\n* Children with poorly controlled CF lung disease\n* Children with advanced CF liver disease\n* Children with a comorbid gastrointestinal disease such as celiac disease, Crohn's disease or other malabsorptive process to be reviewed by PI\n* Children with significant food allergies or other gastrointestinal allergy\n* Family is unwilling to adhere to prescribed dietary intervention","3 Years",{"count":358,"type":23},[26],"There is no study to date that has evaluated the impact or effect of a Mediterranean diet in children with CF. The goal of this study would be to help provide better guidance around questions the investigators, as CF care providers continue to receive from patients and families about how to best promote overall health in pediatric cystic fibrosis from a dietary perspective. Currently, the updated nutritional recommendations are variable and broad. Parents continue to search for more concrete guidance about how best to promote long-term health given the ever-increasing life expectancy of cystic fibrosis patients in this new area of advanced therapeutics. Given the changing landscape of the CF care in general, children are less likely to struggle with early life malnutrition, and it is becoming increasingly clear that high fat, high calorie diets are not beneficial nor are necessary for all children with CF.",[514,515],"Cystic Fibrosis (CF)","Cystic Fibrosis Gastrointestinal Disease",[517,518,519,520,521,522],"cfmed","meddiet","meddiet cf","mediterannean diet","cystic fibrosis","CF with Mediterranean diet","2026-07-01",{"date":525,"type":41},"2026-07-02",{"date":249,"type":23},{"date":458,"type":23},{"name":47,"class":48},{"id":530,"slug":531,"hasResults":12,"nctId":532,"briefTitle":533,"officialTitle":534,"acronym":4,"eligibilityCriteria":535,"healthyVolunteers":12,"sex":536,"minAge":537,"maxAge":538,"enrollmentInfo":539,"targetDuration":4,"studyType":24,"phases":541,"briefSummary":542,"conditions":543,"keywords":544,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":546,"lastUpdatePostDateStruct":547,"startDateStruct":549,"completionDateStruct":551,"leadSponsor":553,"locationsCount":554},"100556243","testing-a-mammography-decision-intervention-in-a-rural-setting-100556243","NCT06522568","Testing a Mammography Decision Intervention in a Rural Setting","Toward Optimization of a Mammography Decision Aid and Clinician Communication Intervention Trial for Rural Settings","Patient Inclusion Criteria:\n\n* Females\n* Aged 39-49\n* Upcoming appointment with a participating primary care provider (within 4 weeks)\n* English or Spanish-speaking\n\nPatient Exclusion Criteria:\n\n* Personal history of breast cancer (including lobular carcinoma in situ and ductal carcinoma in situ or atypical hyperplasia)\n* Mammogram in the prior 12 months\n\nClinician inclusion: Any practicing primary care provider at a participating site.","FEMALE","39 Years","49 Years",{"count":540,"type":23},39,[26],"The overall objective of this COBRE pilot project is to enhance the design of a 3-arm cluster randomized trial that will test the efficacy and mechanism of effect of the MyMammogram DA with or without a provider communication intervention. This will be accomplished through two aims: (1) Refine, with community partner input, a clinical trial protocol to optimize engagement among patients and primary care providers (PCPs) practicing in rural settings. In consultation with patients, PCPs, and informatics experts, the study team will refine site selection, randomization, patient and PCP recruitment, and data collection protocols to meet the needs of the rural health care delivery system and participants. The result of this aim will be a modified protocol and intervention strategy that is acceptable to partners. (2) Adapt and test trial and intervention implementation features to achieve protocol acceptance and adherence. The investigators will pilot the adapted three-arm randomized trial protocol in rural primary care settings that compares the MyMammogram DA with or without a risk summary provided to the PCP pre-visit, relative to usual care. Implementing the trial in two phases (n=15 each) will systematically identify barriers and facilitators to trial participation to refine protocols. Participants will receive acceptability surveys and investigators will conduct qualitative interviews with patients and PCPs to understand experiences with trial implementation from multiple perspectives.",[472],[545],"Screening","2026-06-20",{"date":548,"type":41},"2026-06-24",{"date":550,"type":41},"2025-09-01",{"date":552,"type":23},"2026-09-15",{"name":47,"class":48},3,{"id":556,"slug":557,"hasResults":12,"nctId":558,"briefTitle":559,"officialTitle":560,"acronym":4,"eligibilityCriteria":561,"healthyVolunteers":12,"sex":18,"minAge":82,"maxAge":4,"enrollmentInfo":562,"targetDuration":4,"studyType":24,"phases":564,"briefSummary":565,"conditions":566,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":567,"lastUpdatePostDateStruct":568,"startDateStruct":570,"completionDateStruct":572,"leadSponsor":574,"locationsCount":132},"100535989","a-randomized-two-arm-proof-of-concept-study-testing-a-novel-approach-to-exercise-promotion-based-on-affect-regulation-100535989","NCT06258993","A Randomized Two-Arm Proof of Concept Study Testing A Novel Approach to Exercise Promotion Based on Affect-regulation","Increasing Physical Activity Among Breast Cancer Survivors: Use of the ORBIT Model to Refine and Test a Novel Approach to Exercise Promotion Based on Affect-regulation (Study 2)","Inclusion Criteria:\n\n* ≥18 years old\n* Within 5 years of completing primary cancer treatment (surgery, chemotherapy, and radiation) for Stage 0-III breast cancer\n* \\\u003C60 mins\u002Fweek moderate-vigorous physical activity (MVPA) with no major changes for the past 6- months\n* Own an Android or iPhone smartphone (or tablet) and willing to use it to complete app-based surveys during assessment periods\n* Willing to wear the ActiGraph monitor during assessment periods\n* Access to internet to complete REDCap survey assessments\n\nExclusion Criteria:\n\n* Non-English speaking\u002Fnot able to read English\n* Evidence of major contraindications for exercise (informed by the 2020 Physical Activity Readiness-Questionnaire (PAR-Q)+)\n* Currently pregnant\n* History of severe mental illness or currently taking mood stabilizing medications (antipsychotics, anticonvulsants, or lithium)\n* Evidence of moderate-severe depressive symptoms (indicated by a score≥ 10 on the Patient Health Questionnaire-8)\n* Evidence of moderate-severe cognitive impairment (indicated by a score \\\u003C 3 on a 6-item cognitive screener)\n* Evidence of clinically significant substance use as indicated by a score of ≥ 2 on the CAGE- AID screener.",{"count":563,"type":23},85,[26],"The goal of this clinical trial is to test the effect of an affect-based exercise prescription on moderate-vigorous physical activity participation among survivors of breast cancer who completed primary treatment within the last 5 years. The main questions it aims to answer are:\n\n1. Do at least 50% of participants assigned to the affect-based exercise prescription engage in ≥90 minutes of moderate-vigorous physical activity by the end of 12-weeks follow-up?\n2. What level of satisfaction do breast cancer survivors who receive the affect-based exercise prescription report relative to breast cancer survivors who receive an effort-based exercise prescription.\n3. What proportion of participants assigned to the affect-based exercise prescription stay enrolled in the study relative to the number of participants who stay enrolled in the effort-based exercise prescription.\n\nAll participants will:\n\n* Be assigned to either the Affect-based exercise prescription or the Effort-based exercise prescription.\n* Participate in two meetings with a member of the study team meant to help them get started increasing weekly exercise. These meetings are the same for all participants.\n* Be asked to wear an activity monitor and respond to brief surveys for 10 straight days at 4 points in time: Baseline, 2weeks, 6weeks, and 12weeks.",[472],"2026-06-19",{"date":569,"type":41},"2026-06-23",{"date":571,"type":41},"2024-04-16",{"date":573,"type":23},"2026-08-30",{"name":47,"class":48},{"id":576,"slug":577,"hasResults":12,"nctId":578,"briefTitle":579,"officialTitle":580,"acronym":4,"eligibilityCriteria":581,"healthyVolunteers":12,"sex":18,"minAge":82,"maxAge":4,"enrollmentInfo":582,"targetDuration":4,"studyType":24,"phases":584,"briefSummary":585,"conditions":586,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":591,"lastUpdatePostDateStruct":592,"startDateStruct":594,"completionDateStruct":596,"leadSponsor":598,"locationsCount":132},"100499240","individualized-dose-escalation-of-5-fu-for-gastrointestinal-cancer-100499240","NCT05780684","Individualized Dose Escalation of 5-FU for Gastrointestinal Cancer","Adaptive, Individualized Dose Escalation of Fluorouracil-Based Chemotherapy for Gastrointestinal Cancer: Pilot Study of the FOX Regimen","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Diagnosis of metastatic or locally advanced\u002Finoperable colorectal cancer or non-colorectal gastrointestinal cancer (including cancers of the stomach, esophagus, appendix, small bowel, and ampulla)\n* Clinically appropriate staging imaging of the chest, abdomen, and pelvis performed within 30 days prior to registration\n* ECOG Performance Status: 0-1\n\nExclusion Criteria:\n\n* Any prior receipt of oxaliplatin or fluoropyrimidine chemotherapy (other than radiation-sensitizing fluoropyrimidine chemotherapy)\n* Prior receipt of systemic chemotherapy in the 6 months prior to Day 1 of Cycle 1 of FOX (other than radiation-sensitizing chemotherapy)\n* Known mismatch repair deficiency or microsatellite instability-high disease\n* Known dihydropyrimidine dehydrogenase (DPD) deficiency, as identified by clinically indicated screening\n* Any confirmed second malignancy that is likely to require systemic therapy during the course of the six-month study period, in the opinion of the enrolling investigator\n* Any of the following baseline laboratory abnormalities:\n\n  * Absolute neutrophil count (ANC) \\\u003C 2,500\u002Fmm3\n  * Platelet count \\\u003C 100,000\u002Fmm3\n  * Hemoglobin \\\u003C 9 g\u002FdL\n  * Creatinine \\> 1.5 x ULN\n  * Total bilirubin \\> 1.5 x ULN\n  * AST\u002FALT \\> 5 x ULN\n  * Patients who are unable to provide informed consent\n  * Patients who are pregnant or breastfeeding\n  * Patients who are incarcerated, homeless, or have active substance use disorders",{"count":583,"type":23},36,[26],"This is a single-arm clinical trial to evaluate the feasibility of a chemotherapy regimen using adaptive, individualized dose escalation of 5-FU chemotherapy for patients who have good tolerance of the initial dose. Study participants will also receive oxaliplatin chemotherapy together with 5-FU, at standard doses. The goal of the study is to examine the feasibility and effectiveness of this approach, using individualized dose escalation of 5-FU in patients who do not have serious side effects at lower doses.",[32,587,588,589,590],"Esophagus Cancer","Appendix Cancer","Small Bowel Cancer","Ampullary Cancer","2026-06-18",{"date":593,"type":41},"2026-06-22",{"date":595,"type":41},"2023-07-14",{"date":597,"type":23},"2027-12",{"name":47,"class":48},{"id":600,"slug":601,"hasResults":12,"nctId":602,"briefTitle":603,"officialTitle":604,"acronym":605,"eligibilityCriteria":606,"healthyVolunteers":12,"sex":18,"minAge":82,"maxAge":4,"enrollmentInfo":607,"targetDuration":4,"studyType":24,"phases":609,"briefSummary":610,"conditions":611,"keywords":613,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":621,"lastUpdatePostDateStruct":622,"startDateStruct":624,"completionDateStruct":626,"leadSponsor":628,"locationsCount":4},"100641653","ipath-for-cp-pilot-100641653","NCT07631247","iPath for CP Pilot","Improving Screening and Access to Treatment for Depression in Care Partners of People Living With Dementia","care partners","Inclusion Criteria:\n\n* For 2 Week iPath\\*CP Pilot:\n\n  1. Adults (≥18 years)\n  2. Care partners of persons with dementia who score ≥5 on the PHQ-8 AND PHQ-9 screen\n  3. Can communicate in English\n  4. Have access to an Android based or Apple iOS based phone or tablet capable of running the iPath application.\n\nFor Debrief Interviews:\n\n* Care partners: Interviews will be conducted with a purposeful sample of 6 patients already consented into the study at the completion of T1 data collection, ensuring representation by sex (male\u002Ffemale), perceived usability (low\u002Fhigh) of iPath\\*CP and race\u002Fethnicity.\n* Clinicians: Interviews will be conducted with clinicians and clinical staff who had patients involved in the project.\n\nExclusion Criteria:\n\n* Care partners with:\n\n  1. PHQ-8 score \\\u003C5\n  2. Answering positively for question 9 of the PHQ-9 who also screen positive for suicidal ideation with method, intent, plan or a recent prior suicide\u002Fself-harm attempt, as determined by a positive endorsement of items 3, 4, 5 or 6b (\"Past 3 Months\") on the Columbia-Suicide Severity Rating Scale (C-SSRS) and determined by Dr. Mistler, Psychiatrist at DH, not to be eligible.\n  3. With bipolar disorder or psychosis (documented in the electronic medical record \\[EMR\\])\n  4. With significant cognitive impairment (documented in the EMR or self-reported during eligibility screening)\n  5. With no access to an Android or Apple device\n\nFor Debrief Interviews:\n\n* Patients: Participants withdrawn from the 2 Week iPath\\*CP Pilot.\n* Clinicians: None.",{"count":608,"type":23},15,[26],"Depression is a significant problem in care partners of people living with dementia; despite the expansion of options for accessing evidence-based treatments, most care partners of people living with dementia are not screened for depression and do not receive treatment. The objective of this project is to identify a screening method for depression that is feasible and acceptable to care partners and to adapt an innovative pathway to online evidence-based treatment for depression (iPath\\*D) as a means of increasing mental health literacy, screening rates and treatment access for care partners of people living with dementia. The results are expected to have a major positive impact by providing proof-of-principle for the use of an online pathway to evidence based treatment with the potential for reaching an unprecedented number of care partners who have unmet mental health needs.",[612],"Depression - Major Depressive Disorder",[614,615,616,617,618,619,620],"depression","caregiver","AD\u002FADRD","Alzheimer's disease","dementia","care partner","app","2026-06-12",{"date":623,"type":41},"2026-06-16",{"date":625,"type":23},"2026-06",{"date":627,"type":23},"2027-02",{"name":47,"class":48},""]